schizophrenia

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) March 27 (Reuters) – Researchers have identified a biomarker linked to...

Mar 28 2026

Uncategorized

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

by Clinical Editor

No Comments

Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when …

Mar 28 2026

Uncategorized

Small RNAs offer new clues to schizophrenia and bipolar disorder

by Clinical Editor

No Comments

For decades, scientists studying brain disorders have focused almost exclusively on proteins and the genes encoding them. Now, research from Thomas Jefferson University’s Computational Medicine Center …

Mar 27 2026

Uncategorized

Bristol-Myers Squibb Company: A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models

by Clinical Editor

No Comments

WASHINGTON, D.C. / ACCESS Newswire / March 27, 2026 / Originally published by the National Council for Mental Wellbeing The collaboration’s first initiative is a white paper demonstrating the value...

Mar 27 2026

Uncategorized